This trial is evaluating whether Infliximab will improve 1 primary outcome and 27 secondary outcomes in patients with Depression. Measurement will happen over the course of Baseline, Week 2.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. Infliximab is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"Inflammation is not the only mechanism through which the immune response becomes hypersensitive to inflammatory signals. Tumor necrosis factor-alpha (TNF-α) produced by mast cells, macrophages, and dendritic cells also can contribute to this phenomenon by enhancing the activity of histamine. The increase in histamine activity causes the hypersensitivity to the inflammatory responses in both the intestinal tissue and the extracellular environment." - Anonymous Online Contributor
"When a patient is treated with a medication that affects the immune system, the immune system can also be affected. The human immune system is part of the body's defense against invading microbes or foreign antigens. When inflammation comes from other causes or when it is stimulated by immune system dysfunctions, the inflammation can cause many symptoms, such as physical or emotional discomfort. Inflammation also causes some disease conditions to occur. Thus, an understanding of the function of the human immune system is one of the key aspects for successful and safe medical treatment." - Anonymous Online Contributor
"Around 8 million people in the United States get inflammation a year. However this represents a large number of patients in a narrow age group because only 6.8% of them were between 50 and 69 years of age." - Anonymous Online Contributor
"For the majority of cases, inflammation is the result of a problem with the immune system and can be of many types. There are some cases that are not inflammatory or are caused by infections, where other risk factors such as smoking and exposure to infection are important. Some cases are the result of a number of different kinds of factors, or are unknown. In the majority of cases, however, they are likely to be the result of an infection, and that would certainly lead to inflammation. Those with infectious disease should be treated if they develop symptoms. Those who develop an infection should receive appropriate antibiotics. Those who don't may be treated with steroids. Those who have a specific infection should be treated accordingly." - Anonymous Online Contributor
"Inflammation has many causes. But in any case, an inflammatory response in the lung or intestine will eventually return to the usual homeostatic condition. It is a relatively simple process. Chronic or persistent inflammation cannot be cured." - Anonymous Online Contributor
"The treatments for inflammatory and autoimmune disorders differ. In general, medication can be used to suppress inflammation [4 to 8 weeks/day], but will most likely weaken the immune system and the body may no longer be able to heal itself if other treatments are necessary. If medication has not helped, then surgery may be required. For any surgical procedure, if the person has a health condition that can be improved with the new procedure, then surgery is preferable. [Power](http://wwwnbsb.nbsbox." - Anonymous Online Contributor
"Most common side effects of cetuximab and infliximab in a study population of patients with Crohn's disease included: skin hypersensitivity, headache, diarrhea, itchiness, fatigue, fever, and constipation." - Anonymous Online Contributor
"There is no newly discovered class of medications that target inflammation. Most drug manufacturers do not focus on treating inflammation. Drugs exist that effectively treat arthritis, but do not target inflammation. There are numerous drugs that are effective in treating chronic inflammatory diseases. However, there are not many medications that have been discovered for patients with inflammatory diseases." - Anonymous Online Contributor
"The data suggest that only a carefully-selected subpopulation of inflammatory disease patients would benefit from clinical trial treatment. Clinicians should be cautious about prescribing trials for inflammatory conditions to non-selective patients, regardless of their disease severity." - Anonymous Online Contributor
"Even if the level of interleukin-1β is elevated in inflammatory arthritis, it does not seem to be the only determinant of disease activity. Inflammatory arthritis may also be determined by different mechanisms and it must be taken into account when evaluating patients with rheumatoid arthritis on infliximab." - Anonymous Online Contributor
"The authors found no evidence that treatment with infliximab alone resulted in better clinical improvement than the combination with azathioprine, or that infliximab in combination with adalimumab resulted in greater clinical benefits than the combination with azathioprine." - Anonymous Online Contributor
"Infliximab is safe and well-tolerated in the real-world setting, and may reduce complications compared with other TNF antagonists because of its relative simplicity, once-weekly dosing, dose adjustment based on clinical need, and longer duration of action." - Anonymous Online Contributor